Isolated Pleural Effusion as Presentation of a Large B‐Cell Lymphoma: A Case Report and Diagnostic Considerations Authors: Van Vlierberghe Magalie, Dewaide Rosina, Michaux Lucienne, Develter Wim, Van Aelst Sophie, Claerhout Helena Published: 2026 ABSTRACT ABSTRACTBackgroundFluid Overload‐associated Large B‐Cell Lymphoma (FO‐LBCL) is one of the newly added entities in the WHO classification of Haematolymphoid Tumors 5th edition [1]. Formerly, these cases were classified as primary effusion lymphoma‐like (effusion) lymphoma (PEL‐like (effusion) lymphoma) or HHV8‐unrelated PEL‐like lymphoma. As knowledge grew regarding the differences in clinical presentation and prognosis of these entities, the need for a distinct classification became apparent.MethodWe describe a case of a 79‐year‐old man with acute dyspnea and cough due to massive pleural effusion, revealed by CT scan of the thorax. Further diagnostic evaluation with PET‐CT showed no detectable tumor mass apart from the pleural fluid. Pleural fluid cytology revealed numerous large atypical lymphoid cells. Flow cytometric immunophenotyping showed a predominant monoclonal CD19+/CD20+ B‐cell population with light chain restriction and CD5 expression. Molecular analysis demonstrated partial clonality, and cytogenetics revealed a complex hyperdiploid karyotype. EBV in situ hybridization and testing for HHV8 and HIV were negative. No underlying immunodeficiency or systemic disease was identified.Results and ConclusionBased on these findings, diagnosis was most consistent with FO‐LBCL, but distinction from other HHV8‐negative effusion‐based large B‐cell lymphomas remains challenging due to overlapping features. The patient received R‐CHOP‐based immunochemotherapy and remains clinically stable without systemic progression. This case highlights the critical role of integrated cytologic, immunophenotypic, molecular, and virological analyses in establishing the correct classification of effusion‐based large B‐cell lymphomas and underscores the diagnostic challenges posed by this emerging entity. Accurate recognition of FO‐LBCL is essential, as its clinical behavior and therapeutic implications differ from other effusion‐based lymphomas.Keywords: case report, diagnosis, DLBCL‐NOS, FO‐LBCL, PEL‐like lymphoma Introduction The 5th edition of the WHO Classification of Haematolymphoid Tumors (WHO‐HAEM5) introduced a novel entity within the family of the Diffuse Large B‐Cell Lymphomas (DLBCL): Fluid Overload‐associated Large‐B Cell Lymphoma (FO‐LBCL). Before the recognition of this new entity, clinicians often classified it as ‘primary effusion lymphoma (PEL)‐like lymphomas’, ‘Kaposi's sarcoma‐associated herpesvirus/human herpesvirus 8‐negative PEL’ (KSHV/HHV8‐negative PEL), or ‘HHV8‐unrelated PEL‐like lymphoma’ [1]. The prevalence remains undetermined due to the rarity of these conditions [2]. The distinct cytomorphology, site of effusions, absence of solid tumor mass, and lack of MYC rearrangements all bear resemblance to those observed in PEL [3]. As of 2022, the new entity has been classified ‘Fluid Overload‐associated Large B‐Cell Lymphoma’ (WHO‐HAEM5) or ‘KSHV/HHV8‐negative effusion‐based lymphomas’ (KSHV/HHV8‐negative EBLs) (ICC, International Consensus Classification of Mature Lymphoid Neoplasms, 2022) [1, 4]. To the best of our knowledge, there are only a few case reports describing the condition under its newly recognized entity. Clinical experience with the WHO and ICC classifications continuously guides experts in refining the classification, ensuring accurate diagnoses and optimal patient care [4]. This case report adds to the growing body of evidence guiding potential reclassifications of diseases based on clinical outcomes and treatment responses. Case Description A 79‐year‐old man with a medical history of multiple cutaneous squamous cell carcinomas, stage pT1 grade 2–3, and giant basal cell carcinoma presented with acute dyspnea and cough. Computed tomography (CT) of the thorax (Figure 1) revealed a massive pleural effusion in the right hemithorax, along with moderately scattered pleural effusion posteriorly in the left hemithorax. No lymphadenopathy, pericardial effusion, or other abnormalities were noted in the upper abdomen. A PET‐CT scan confirmed significant bilateral pleural effusion with atelectasis of both lung bases without detectable tumor mass elsewhere. There was no pleural thickening nor calcifications. Pleural fluid analysis showed: glucose 75.0 mg/dL, protein 50.0 g/L, LDH 961 U/L, CEA 0.43 μg/L, and pH 6.7. According to Light's criteria, the pleural effusion was classified as an exudate, with a pleural fluid protein/serum protein ratio of 0.7 (> 0.5) and a pleural fluid LDH/serum LDH ratio of 5 (> 0.6). Cardiac investigation based on ultrasound showed no evidence for the presence of conditions causing fluid overload. Furthermore, eGFR showed no kidney disease, and albumin concentration, AST, and ALT were within normal limits. Computed tomography (CT) scan of the thorax demonstrating massive pleural effusion in the right hemithorax and moderately pronounced pleural effusion posteriorly in the left hemithorax. Cytological examination of the pleural fluid using May‐Grünwald‐Giemsa staining revealed the presence of numerous atypical cells characterized by medium to large size, predominantly solitary but occasionally clustered arrangement, a high nucleus‐to‐cytoplasm ratio, irregular nucleus contours, prominent vacuolization, dark basophilic cytoplasm, and ragged cytoplasmic borders (Figure 2). Flow cytometric immunophenotyping identified 97% lymphocytes, of which 79% were B‐cells (CD19+) with light chain restriction. This large population of monoclonal B‐cells showed positivity for CD5 and expressed mature B‐cell markers: high side scatter (SSC) and expression of CD45 (strong), CD19 (weak), CD20, CD5, CD200, and FMC7 (weak), while negative for CD10, CD23, CD43, CD79b, and CD38. MCL was considered, but morphology and peripheral blood findings were inconsistent. CLL transformation was excluded on clinical and immunophenotypic grounds: the patient showed no clinical history of CLL, there was no lymphocytosis, nor were monoclonal B‐cells identified in the peripheral blood, and CD23 and CD43 were negative with immunophenotyping. Cytological examination (500× magnification, May‐Grünwald‐Giemsa stain) revealed the presence of numerous large, atypical cells. PCR analysis was suggestive, but not typical, of B‐cell clonality (polyclonal pattern for IgF‐FR1, FR2, FR3, and IGK‐A and monoclonal pattern for IGK‐B on a polyclonal background). FISH analysis showed no MYC rearrangements. This ruled out the possibility of Burkitt lymphoma or double/triple hit lymphoma. Conventional cytogenetic analysis revealed a complex hyperdiploid karyotype without specific aberration: 50,XY,add(2)(q22),add(6)(q16?),‑8,‑9,add(13)(q34),‑16,+7‐8mar,inc[cp5]. Histopathology and immunohistochemistry of the pleural fluid were performed. Pax5 staining showed an increased proportion of B‐cells with a large cell aspect, LCA (leukocyte common antigen, CD45) staining showed large cells suspicious for a large‐cell lymphoma, and stains for desmin, EMA, WT1, and CEA showed absent immunoreactivity. Epstein–Barr virus (EBV) in situ hybridization was negative. Furthermore, immunohistochemical analysis for CD5 and CD20 displayed a mixed population of large cells with intermediate reactive T‐cells. Complete blood count showed no cytopenia, but mild thrombocytosis and lymphopenia. Protein electrophoresis on the fluid and serum did not reveal the presence of a paraprotein. Serologic testing for hepatitis B and C, HIV tests, and HHV8‐PCR yielded negative results. Based on the clinical presentation of an isolated serous effusion without detectable mass lesion, absence of underlying immunodeficiency, negativity for HHV8, HIV, and EBV, and an immunophenotype consistent with a mature B‐cell neoplasm, the patient was tentatively diagnosed with a B‐cell lymphoma presenting as an isolated effusion, most compatible with FO‐LBCL. The relatively indolent clinical course and the absence of immunodeficiency further support FO‐LBCL in this case. However, given the overlapping clinicopathological features with PEL‐like lymphoma, HHV8‐unrelated PEL, and primary HHV8‐negative EBL, a definitive distinction remains challenging. The patient was treated as having a CD20‐positive large B‐cell lymphoma with combined immunochemotherapy according to the R‐CHOP‐21 regimen, comprising rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2) and vincristine (1.4 mg/m2; maximum 2.0 mg) with a 50% dose reduction of doxorubicin and vincristine because of advanced age. A maximum of six cycles was planned. After three cycles, persistent right‐sided pleural effusion prompted thoracoscopy with pleural biopsy and talc pleurodesis. Talc pleurodesis was performed to provide symptomatic relief and prevent recurrence. We acknowledge that talc‐induced pleural inflammation may potentially complicate radiological response assessment in lymphoma. Biopsy and pleural fluid analyses at that time were negative for monoclonal B cells, suggesting treatment response. No further lymphoma‐directed therapy was administered. The patient has remained clinically stable, although with persistent pleural effusion (predominantly left‐sided due to right‐sided pleurodesis) and stable pulmonary status. Repeat analysis of pleural fluid approximately 6, 12, and 18 months after therapy remained negative for aberrant or monoclonal B cells. To date, there is no clear explanation for the persistence and slow progression of this pleural effusion. A few months after cessation of R‐CHOP, he developed a relapse of his cutaneous squamous cell carcinoma, stage pT3 grade 3, at a previous resection side for which he was started on immunotherapy with cemiplimab. Discussion Differential Diagnosis Within the family of DLBCL, there are 18 entities. DLBCL‐NOS (Not Otherwise Specified) is the largest entity, accounting for 80% of the DLBCL cases [5]. Generally, DLBCL‐NOS are characterized by morphology and by a mature B‐cell phenotype, often lacking distinctive features from each other based on clinicopathological findings and behavior. Distinction of subtypes addressing the morphological, phenotypical, genotypical, and/or clinical aspects is necessary for correct follow‐up, treatment, and prognostic considerations [1]. The main clinicopathological feature of our case report is the presence of lymphoma cells in fluid from a body cavity without a detectable tumor mass. Based on mentioned findings, the differential diagnoses for this case are DLBCL‐NOS, PEL, HHV‐8, and EBV‐negative primary EBL and FO‐LBCL. A comparative overview of the key clinicopathological features of these entities is provided in Table 1. This case best meets the criteria of FO‐LBCL according to the WHO HAEM5 classification. The absence of an identifiable fluid overload condition weakens the strict classification but is not strictly required as a pre‐existing condition. We do acknowledge that according to the ICC 2022 classification, this case could be classified as HHV‐8 and EBV‐negative primary effusion‐based lymphoma. TABLE 1A comparative overview summarizing the main clinicopathological features of FO‐LBCL, PEL, DLBCL‐NOS, and HHV‐8 and EBV‐negative primary EBL.FeatureFO‐LBCL (WHO‐HAEM5)PEL (WHO‐HAEM5)DLBCL‐NOS (WHO‐HAEM5, ICC 2022)HHV‐8 and EBV‐negative primary EBL (ICC 2022)SiteSerous cavitiesSerous cavitiesNodal or extranodal massesSerous cavitiesSolid tumor massAbsentAbsentPresentAbsentHHV8NegativePositiveNegativeNegativeEBV13%–30% positiveUsually positiveNot requiredNegativeHIVNegativeUsually positiveNot requiredNegativeImmunodeficiencyAbsentTypically presentNot requiredAbsentFluid overload conditionCommon (> 50%)Not typicalNot requiredCommonMorphologyImmunoblastic/anaplasticImmunoblastic/plasmablasticCentroblastic/immunoblastic/anaplasticCentroblastic/immunoblasticCD20 expressionUsually positive (~80%)NegativeUsually positive≥ 1 B‐cell markerMYC rearrangementMay occur (< 50%)RareMay occurMay occur (~20%)Typical ageElderly (70–77 years)Younger/immunocompromisedVariable (more commonly with increasing age)ElderlyPrognosisFavorableRelatively poorVariableGood A comparative overview summarizing the main clinicopathological features of FO‐LBCL, PEL, DLBCL‐NOS, and HHV‐8 and EBV‐negative primary EBL. Epidemiology Patients with FO‐LBCL are generally older (median 70 y) with a slight male‐to‐female predilection and are by definition not immunosuppressed [6]. More than 50% of the patients have an underlying medical condition leading to fluid overload, including cirrhosis, protein‐losing enteropathy, and cardiac problems [3]. PEL most often presents in immunocompromised patients: older patients, patients co‐infected with EBV and/or HIV, and/or patients in a post‐transplant setting. The median age of diagnosis is about 45 years [5, 7]. The male‐to‐female ratio approaches 8:2 [8]. In our case report, the patient is not immunocompromised nor diagnosed with an underlying medical condition leading to fluid overload. Pathophysiology, Localization, Clinical Presentation FO‐LBCL does not typically exhibit radiologically evident thickening of serosal membranes, and EBV positivity is noted in nearly 30% of cases [3]. The pathogenesis of FO‐LBCL is not yet fully understood, with some authors proposing a significant role for abnormalities in PAX5, multistep genomic alterations such as trisomy 8, aberrations of MYC, and/or the lymphotropic properties of HCV [9, 10]. Most effusions are localized within the pleura (66.7%), while other locations include the peritoneum (37.8%) and pericardium (26.7%). Multiple sites of effusion may occur [3]. Cytology: Microscopy and Immunophenotyping Lymphoma cells in FO‐LBCL are medium to large with pleomorphic, immunoblastic, or plasmablastic morphology. The cells express pan‐B‐cell antigens (86.7%), defined as CD19, CD20, CD22, CD79a, or cytoplasmic/surface immunoglobulin. The lymphoma typically exhibits characteristics resembling either germinal center B‐cells (GCB) or a combination of germinal center B‐cells and activated B‐cells (ABC) [3]. Expression of CD20 forms a significant difference between PEL and FO‐LBCL, as it is the primary target of rituximab [3]. Cytogenetics (Including Karyotyping and FISH Analysis) In the literature review by Alexanian S. et al. (2013), 17 cases with available cytogenetic data were identified, most of which demonstrated a complex karyotype without “specific” abnormality. In addition, 82.6% of the reviewed cases lacked rearrangement of MYC [3]. The genomic landscape has been reported to be complex and similar to conventional DLBCL, with frequent mutations (commonly HIST1H1E and MYD88) [11, 12]. Treatment, Prognosis, Clinical Outcome DLBCL is known to be a rapidly growing, aggressive type of B‐NHL (B‐cell non‐Hodgkin lymphoma). However, it often responds well to six cycles of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) [13]. Clinical outcome and response to therapy, including standalone pleural effusion drainage, in patients with FO‐LBCL are relatively favorable compared with cases of PEL [3, 7]. FO‐LBCL would have a median survival exceeding 10 months [14] and a reported 2‐year overall survival rate of 87.4% [2]. FO‐LBCL, typically CD20 positive, has a better outcome than PEL, mostly due to the possibility of using rituximab [7]. CHOP or comparable regimens are advised for systemic chemotherapy in patients without significant contraindications or comorbidities. For patients with extended survival prospects, administering R‐CHOP following fluid drainage may provide advantages [12]. For individuals unable to tolerate chemotherapy or for elderly patients with severe complications who are unlikely to benefit from such treatment, standalone pleural effusion drainage might be a viable alternative [10]. Conclusion This case illustrates an uncommon presentation of a large B‐cell lymphoma confined to pleural effusion, without associated mass lesions. According to the 5th edition of the WHO classification and the 2022 International Consensus Classification of Mature Lymphoid Neoplasms (ICC), such effusion‐based lymphomas may be categorized as FO‐LBCL or as HHV8‐ and EBV‐negative PEL [1, 4]. To date, only a limited number of FO‐LBCL cases have been reported, and the distinction between these overlapping entities remains challenging, as seen in our case. Our observation underscores the need for further studies to refine diagnostic criteria and to establish evidence‐based management strategies for patients with effusion‐based large B‐cell lymphomas. Author Contributions Van Vlierberghe Magalie writing – original draft preparation; Claerhout Helena and Van Aelst Sophie writing – review and editing – supervision; Dewaide Rosina – clinical examination and therapy; Develter Wim – interpretation of pathological data; Michaux Lucienne – interpretation of molecular data. All authors read and approved the final manuscript. Funding The authors have nothing to report. Ethics Statement Written informed consent was not required because all the information is anonymized, and the submission does not include images that may identify the person. This article has been written in accordance with the ethical standards of the institution and considering the case report guidelines [CARE]. Consent Consent was not required due to the anonymized information and images that are used in this case report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements This research was supported by the Heilig Hart Hospital in Lier. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author.